Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)
Summary
This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.
Arms & interventions
- OtherTargeted Therapy
Approved interventions based on the subject's genomic profile will be provided to investigators for consideration for anti-tumor therapy.
Outcome measures
Primary
Number of Subjects Receiving Targeted Therapy
This measure is the number of study subject's whose treating physician prescribes and subsequently receives the therapeutic recommendation of the Molecular Tumor Board.
Time frame: 5 years
Eligibility criteria
Study locations (1)
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226